These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37747615)

  • 1. Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: improved discrimination with a cancer-specific scale.
    Bulamu NB; Chen G; McGrane E; Cock C; Young GP; Symonds EL
    Cancer Causes Control; 2024 Feb; 35(2):347-357. PubMed ID: 37747615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy.
    Bulamu NB; Vissapragada R; Chen G; Ratcliffe J; Mudge LA; Smithers BM; Isenring EA; Smith L; Jamieson GG; Watson DI;
    Health Qual Life Outcomes; 2021 Oct; 19(1):233. PubMed ID: 34600554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients.
    Pan CW; He JY; Zhu YB; Zhao CH; Luo N; Wang P
    Eur J Health Econ; 2023 Aug; 24(6):885-893. PubMed ID: 36083356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
    Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
    Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Japanese value set for the EORTC QLU-C10D: A multi-attribute utility instrument based on the EORTC QLQ-C30 cancer-specific quality-of-life questionnaire.
    Shiroiwa T; King MT; Norman R; Müller F; Campbell R; Kemmler G; Murata T; Shimozuma K; Fukuda T
    Qual Life Res; 2024 Jul; 33(7):1865-1879. PubMed ID: 38724771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of Health-Related Utilities for
    Soare IA; Leeuwenkamp O; Longworth L
    Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
    Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
    J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values.
    van Gelder T; Mulhern B; Schoormans D; Husson O; De Abreu Lourenço R
    Qual Life Res; 2020 Jun; 29(6):1483-1494. PubMed ID: 31938965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.
    King MT; Viney R; Simon Pickard A; Rowen D; Aaronson NK; Brazier JE; Cella D; Costa DSJ; Fayers PM; Kemmler G; McTaggart-Cowen H; Mercieca-Bebber R; Peacock S; Street DJ; Young TA; Norman R;
    Pharmacoeconomics; 2018 Feb; 36(2):225-238. PubMed ID: 29270835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
    Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
    Pharmacoecon Open; 2024 Jul; 8(4):627-640. PubMed ID: 38696019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument.
    Revicki DA; King MT; Viney R; Pickard AS; Mercieca-Bebber R; Shaw JW; Müller F; Norman R
    Med Decis Making; 2021 May; 41(4):485-501. PubMed ID: 33813946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30.
    Nerich V; Gamper EM; Norman R; King M; Holzner B; Viney R; Kemmler G
    Appl Health Econ Health Policy; 2021 Mar; 19(2):191-202. PubMed ID: 32537694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30.
    Kemmler G; Gamper E; Nerich V; Norman R; Viney R; Holzner B; King M;
    Qual Life Res; 2019 Dec; 28(12):3197-3211. PubMed ID: 31485913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.
    Pilz MJ; Seyringer S; Hallsson LR; Bottomley A; Jansen F; King MT; Norman R; Rutten MJ; Verdonck-de Leeuw IM; Siersema PD; Gamper EM
    Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38483665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D.
    Jansen F; Verdonck-de Leeuw IM; Gamper E; Norman R; Holzner B; King M; Kemmler G;
    Qual Life Res; 2021 Jul; 30(7):2009-2019. PubMed ID: 33512653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
    Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
    Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score.
    Klapproth CP; Fischer F; Rose M; Karsten MM
    J Clin Epidemiol; 2022 Dec; 152():101-109. PubMed ID: 36162712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
    Kim H; Cook G; Goodall S; Liew D
    Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30.
    McTaggart-Cowan H; King MT; Norman R; Costa DSJ; Pickard AS; Regier DA; Viney R; Peacock SJ
    MDM Policy Pract; 2019; 4(1):2381468319842532. PubMed ID: 31245606
    [No Abstract]   [Full Text] [Related]  

  • 20. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.
    King MT; Costa DS; Aaronson NK; Brazier JE; Cella DF; Fayers PM; Grimison P; Janda M; Kemmler G; Norman R; Pickard AS; Rowen D; Velikova G; Young TA; Viney R
    Qual Life Res; 2016 Mar; 25(3):625-36. PubMed ID: 26790428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.